Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Interstitial cystitis
- Focus Therapeutic Use
- 01 Mar 2017 Planned End Date changed from 1 May 2018 to 1 Jul 2017.
- 01 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 1 May 2017.
- 01 Mar 2017 Status changed from recruiting to active, no longer recruiting.